Nationwide

Seven in ten women investors are rethinking if and when they can retire

Retrieved on: 
Tuesday, March 12, 2024
Transfer, Baby boomers, Partnership, Female, Nationwide Mutual Insurance Company, Senior, Marketing, Woman, Health administration, Nationwide, Adviser, Retirement, Retention, ETF, Financial adviser

COLUMBUS, Ohio, March 12, 2024 /PRNewswire/ -- Uncertain market conditions and the rising cost of living are significantly impacting women investors and their retirement plans. As they grapple with cascading economic headwinds, seven in ten (70%) women investors say that inflation and signs of a potential recession have made them rethink if and when they can retire, according to Nationwide's ninth annual Advisor Authority survey, powered by the Nationwide Retirement Institute.

Key Points: 
  • As the number of single older Americans steadily grows , single women in particular are grappling with unique circumstances.
  • Compounding this concern, more than four in ten single women (44%) are worried about their ability to afford monthly bills in retirement.
  • Single women tend to be more proactive than married women when it comes to discussing retirement planning with their advisor.
  • Single women (27%) are slightly more likely to discuss converting accumulated savings into retirement income with their advisor than are married women (22%).

Celly and Cyclum Renewable Truck Stops Announce Initial Agreement to Revolutionize Truck Stop Hydrogen Infrastructure

Retrieved on: 
Monday, March 11, 2024
Hydrogen, Strategic management, EV, Green hydrogen, Natural gas, Original equipment manufacturer, Partnership, Interstate Highway System, CNG, Marketing, OEM, Nationwide, Restaurant, Goal celebration, Financial analyst, Truck driver, RNG, HRS

HOUSTON, March 11, 2024 /PRNewswire-PRWeb/ -- Revolutionizing the energy industry with green Hydrogen, Celly is a dynamic business driving change. Based in Texas, Celly H2 LLC stands poised to redefine industry norms as a leading distributor of green hydrogen fuel. With a steadfast dedication to delivering clean, reliable, and cost-effective energy alternatives, Celly emerges as the ideal ally for Cyclum and others seeking sustainable energy solutions. Their comprehensive services span from delivering and dispensing low CI hydrogen to cutting-edge modular refueling stations, encompassing operations, maintenance, and logistics, placing Celly at the vanguard of a greener tomorrow. Inspired by successful models in Europe, Celly is committed to sustainability and efficiency, offering hydrogen fuels tailored for municipalities, transit authorities, fleet owners, industrial users, refineries, ports, and businesses alike. Embracing an innovative "drop and swap" approach to hydrogen transport, Celly epitomizes the future of sustainable energy distribution.

Key Points: 
  • Celly and Cyclum have forged a groundbreaking partnership aimed at revolutionizing truck stop infrastructure and advancing sustainable energy solutions.
  • Leveraging Celly's expertise in green hydrogen distribution and Cyclum's innovative approach to truck stop design, the partnership seeks to integrate state-of-the-art Celly Hydrogen Refueling Stations (HRS) at Cyclum Truck Stop locations across California and Florida.
  • This next level in the Truck Stop Industry aligns perfectly with Celly's expertise in designing and implementing Hydrogen sustainable solutions.
  • In collaboration, Cyclum and Celly are excited to join forces and pioneer the future of truck stop infrastructure.

CoreCivic Appoints Catherine Hernandez-Blades and Alexander R. Fischer to its Board of Directors; CoreCivic Also Announces Planned Retirement of Long-Term Board Member Donna Alvarado

Retrieved on: 
Thursday, March 7, 2024
Ohio State University, Seminar, CoreCivic, University, Aflac, Annual general meeting, Advisory board, Federation, Marketing, Economic development, SAIC, Raytheon Technologies, WMS, Mass communication, Hospital, Battelle Memorial Institute, CXW, Partner, Business, Chair, Operation Homefront, Commissioner, Commercialization, Advanced Drainage Systems, Nationwide, Flex (company), Trustee, Government, Audit committee, Executive, Lockheed, Management

Both Ms. Hernandez-Blades and Mr. Fischer are expected to join various board committees in the future.

Key Points: 
  • Both Ms. Hernandez-Blades and Mr. Fischer are expected to join various board committees in the future.
  • "We are pleased to have Catherine and Alex join our Board of Directors," said Damon Hininger, CoreCivic's President and Chief Executive Officer.
  • "Catherine brings decades of executive leadership experience in government relations, communications, and marketing in both the private and the public sectors.
  • Catherine also provides community support as a board member at several non-profits.

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

Retrieved on: 
Monday, March 4, 2024
Bangladesh Technical Education Board, Natural history, Gene, Nationwide, NIH, ATPase, FDA, Fortress Biotech, Food, Cerebrospinal fluid, Hospital, Principal investigator, Gene therapy, Human, Research institute, Therapy, Menkes disease, Patient, X-linked recessive inheritance, Cyprium, CSF, Clinical trial, Pediatrics, Fortification, Male, Genetics, Mutation, Spinal muscular atrophy, Copper, NDA, Orphan, AAV, DSM-IV codes, Research, Mouse, Pharmaceutical industry

MIAMI, March 04, 2024 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), today announced that the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) has awarded a three-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital and Principal Investigator, Stephen G. Kaler, M.D., M.P.H., to fund completion of preclinical studies, manufacturing and preparation of an Investigational New Drug Application for a first-in-human clinical trial to advance adeno-associated virus (“AAV”)-ATP7A gene therapy, also known as AAV-ATP7A, for the treatment of Menkes disease.

Key Points: 
  • Often lethal if untreated, Menkes disease is an X-linked recessive disorder of copper metabolism caused by mutations in ATP7A, an evolutionarily conserved copper-transporting ATPase.
  • “By combining CUTX-101 with working copies of ATP7A delivered by AAV, we hope to enhance clinical outcomes in Menkes disease, a fatal rare pediatric disease.
  • Preclinical studies have demonstrated a synergistic effect of AAV-ATP7A and CUTX-101 in a reliable mouse model of Menkes disease.
  • In early studies, cerebrospinal fluid (“CSF”)-directed AAV gene therapy rescued 22-53% of mice with a mutation in the human Menkes disease homolog (mottled-brindled) when combined with CSF or subcutaneous copper.

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Retrieved on: 
Monday, February 26, 2024
Infection, Bangladesh Technical Education Board, Division, Amphotericin B, Palliative care, Recurrence, University, Doctor of Philosophy, Malignancy, Nationwide, Physician, City, Azole, Hospital, Cryptococcosis, Nephrotoxicity, Skin, Aspergillosis, Fusarium, Lung, Fungal infection, Johns Hopkins, Vanderbilt University Medical Center, LNC, Coccidioides, Patient, Coccidioidomycosis, Histoplasmosis, Brain, Pharmaceutical industry

BEDMINSTER, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today provided an update from its ongoing Compassionate/Expanded Use Access Program (the “Program”) with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

Key Points: 
  • Treatment with MAT2203 was well tolerated and led to favorable clinical and radiological response and we did not observe any renal toxicity.
  • 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned.
  • 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease.
  • “We continue to be excited about the ongoing, consistent positive clinical impact of MAT2203, seen in these extremely ill patients,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas .

Sprout Social Announces Fourth Quarter 2023 Financial Results Above Guidance Range

Retrieved on: 
Tuesday, February 20, 2024
Online, G2, CFO, SMB, Reddit, Social media, American Honda Motor Company, SPT, Nationwide, Average cost, Growth, Hospital, Sprout, Commerce, The CW, DHL International Aviation ME, Panasonic, BD (company), Parent, ARR, RPO, GAAP, CoStar Group, Brown–Forman, Central Time, Software, Partnership, Video game

CHICAGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2023.

Key Points: 
  • CHICAGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2023.
  • “We’re pleased to share incredibly strong fourth quarter results,” said Justyn Howard, Sprout Social’s CEO and co-founder.
  • Non-GAAP operating income was $1.7 million, compared to $0.6 million in the fourth quarter of 2022.
  • Non-GAAP net income was $1.0 million, compared to $1.8 million in the fourth quarter of 2022.

CLARA Analytics Achieves Record Revenue Growth, Accelerates Innovation

Retrieved on: 
Wednesday, March 6, 2024
Technology, Insurance, Professional Services, Health Insurance, Software, Health, Data Analytics, Data Management, Artificial Intelligence, Digital Life, Roger Hawkins (drummer), Artificial intelligence, AI, Intelligence, Research, Nationwide, ROI, Growth, ARR, Triage, CLARA, Berkshire Hathaway, Publication, Optics, Partnership

The platform includes CLARA Triage , CLARA Treatment , CLARA Litigation , CLARA Optics and CLARA MSP Compliance modules, which enable claims professionals to choose specific capabilities to tackle their rising insurance claims challenges.

Key Points: 
  • The platform includes CLARA Triage , CLARA Treatment , CLARA Litigation , CLARA Optics and CLARA MSP Compliance modules, which enable claims professionals to choose specific capabilities to tackle their rising insurance claims challenges.
  • “Investors, industry leaders, and analysts are responding extremely positively to CLARA’s rapid growth and customer success,” said CLARA Analytics CEO Heather H. Wilson .
  • Last month, CLARA announced yet another infusion of capital from Nationwide Ventures , which invests in companies that are shaping the future of insurance and financial services.
  • CLARA’s growth is fueled by its track record of delivering strong ROI for its customers, along with its reputation for industry-leading innovation and customer service.

MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Children, Biotechnology, Health, Pharmaceutical, Oncology, Research, Family, Hospitals, Consumer, Science, Clinical Trials, Cancer, Central nervous system, Radiation, Immune system, MAIA, Ohio State University, Cell proliferation, Nationwide Children's Hospital, Nationwide, Hospital, Brain, AACR, Survival rate, Prognosis, CNS, Associate, Survival, Immunotherapy, DIPG

The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.

Key Points: 
  • The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.
  • The study explored the combination of THIO and ionizing radiation (IR) treatments to induce direct anticancer effects and stimulate anti-tumor immunity in diffuse intrinsic pontine glioma (DIPG).
  • DIPG, a very difficult-to-treat and high-risk childhood cancer, is a central nervous system (CNS) tumor that forms in the brainstem.
  • Scientists from Nationwide Children’s Hospital and MAIA have shown that THIO synergistically sensitizes DIPG cells to ionizing radiation (IR), significantly decreasing cell proliferation.

DALBAR’s Universal Life Web Review Identifies Providers Achieving Self-Service Excellence

Retrieved on: 
Wednesday, March 6, 2024
Finance, Consulting, Accounting, Professional Services, Insurance, Universal life insurance, Lincoln National Corporation, Thrivent, Universal Life, History, Government, Nationwide, Function

DALBAR has completed their annual review of website experiences offered to potential and existing Universal Life Insurance customers, and is recognizing providers whose websites earned high scores in 2023.

Key Points: 
  • DALBAR has completed their annual review of website experiences offered to potential and existing Universal Life Insurance customers, and is recognizing providers whose websites earned high scores in 2023.
  • Life insurance is an important consideration and these firms excel in supporting both the search for products and service to policyholders.
  • John Hancock's Universal Life experience excels holistically, ranking within the top 5 across all evaluation areas.
  • For more information, or to find out if your firm was included in DALBAR’s Universal Life website review, email [email protected] .

The ODP Corporation Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024
Supply Chain Management, Online Retail, Retail, Other Retail, Specialty, Office Products, The ODP Corporation, Total, Share repurchase, ODP, Nationwide, Personal protective equipment, Tech, Small business, Smith, Growth, FILO, GAAP, Capital expenditure, PPE, OfficeMax, Capital, E-commerce, Depreciation, Video game

Operating results in the fourth quarter of 2023 included $74 million of charges, primarily related to a $68 million non-cash impairment of goodwill in its Varis business unit.

Key Points: 
  • Operating results in the fourth quarter of 2023 included $74 million of charges, primarily related to a $68 million non-cash impairment of goodwill in its Varis business unit.
  • Adjusted results for the fourth quarter of 2023 exclude charges and credits totaling $74 million as described above and the associated tax impacts.
  • Fourth quarter of 2023 adjusted EBITDA was $73 million compared to $89 million in the prior year period.
  • Adjusted Free Cash Flow(3) was $43 million in the fourth quarter of 2023, compared to $147 million in the prior year period.